suedunnell wrote: Hi Again - I should add my name to comment #1 above and ask that if anyone has questions, they can either post them here or ask me directly:
Sue Dunnell
PowerBuilder Product Manager
978 287 1752
sue.dunnell@sybase.com
WHEAT RIDGE, CO -- (MARKET WIRE) -- 05/08/07 -- GeneThera, Inc. (OTCBB: GTHA) announced today
that Canada's Canadian Food Inspection Agency has confirmed Canada's 10th
case of Mad Cow.
The agency says it appears the 5 1/2-year-old cow was exposed to a small
amount of infected material, likely during its first year of life. The
agency is now checking other animals born about the same time and is trying
to find out how the infection happened. In April of last year, another
Canadian dairy cow was found with mad cow disease, or bovine spongiform
encephalopathy, and the food inspection agency said that case was caused by
contaminated feed.
Eating meat products contaminated with Mad Cow has been linked to more than
150 human deaths, mostly in Britain, from variant Creutzfeldt-Jakob
Disease, a rare and nerve disease.
There have been three confirmed cases of mad cow disease in U.S. animals.
ABOUT GENETHERA, INC.:
GeneThera, Inc. is a molecular biotechnology company located in Wheat
Ridge, CO. The Company provides genetic diagnostic solutions for the
veterinary and agricultural industries with future plans to include the
health-care industry.
"Safe Harbor" Statement: Certain statements in this release are
"forward-looking" statements as defined in the Private Securities
Litigation Reform Act of 1995. Such statements are subject to numerous
risks and uncertainties. Actual results may vary significantly from the
results expressed or implied in such statements. Factors that could cause
actual results to materially differ from forward-looking statements
include, but are not limited to, the Company's ability to meet the terms
and conditions required to obtain its project financing, risks and delays
associated with product development, risk of market acceptance of new
products, risk of technology or product obsolescence, competitive risks,
reliance on development partners and the need for additional capital.